Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
Author:
Affiliation:
1. Shanghai Henlius Biotech, Inc., Shanghai, China
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/19420862.2019.1578147
Reference29 articles.
1. Marketed therapeutic antibodies compendium
2. The State of the Art in the Development of Biosimilars
3. Biosimilar, biobetter and next generation therapeutic antibodies
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics;J PHARM ANAL;2024
2. Overview of tumor immunotherapy based on approved drugs;Life Sciences;2024-03
3. Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability;Molecular Pharmaceutics;2024-02-29
4. The current status of the biosimilars landscape in China;Biologicals;2024-02
5. Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study;BMC Cancer;2024-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3